Navidea Biopharmaceuticals, Inc.
NAVBDelisted Jan 16, 2024- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000810509
Navidea Biopharmaceuticals, Inc. was delisted on Jan 16, 2024; its insiders filed their last Form 4 on Dec 5, 2023; 24 institutions reported holding it in 13F filings for Q3 2023, worth $225.8K in total; no superinvestor held it.
13F holders, Q3 2023
Institutional positions in Navidea Biopharmaceuticals, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
NAVB is no longer listed, so this page shows Q3 2023. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 24
- +1 vs. Q2 2023
- Shares held
- 2.52M
- +1.01M (+67.1%) vs. Q2 2023
- Total value
- $225.8K
- +$87.3K (+63.0%) vs. Q2 2023
- New holders
- 4
- 6 more added
- Sold out
- 3
- 2 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NAVB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 2 | $0 |
| Q3 2025 | 1 | $0 |
| Q2 2025 | 1 | $0 |
| Q1 2025 | 2 | $0 |
| Q4 2024 | 1 | $0 |
| Q3 2024 | 2 | $0 |
| Q2 2024 | 2 | $0 |
| Q1 2024 | 2 | $13 |
| Q4 2023 | 4 | $469 |
| Q3 2023 | 24 | $225.8K |
| Q2 2023 | 23 | $138.5K |
| Q1 2023 | 30 | $364.4K |
| Q4 2022 | 28 | $339.3K |
| Q3 2022 | 25 | $379.6K |
| Q2 2022 | 26 | $1.08M |
| Q1 2022 | 25 | $1.19M |
| Q4 2021 | 31 | $1.68M |
| Q3 2021 | 29 | $2.76M |
| Q2 2021 | 31 | $3.08M |
| Q1 2021 | 35 | $3.77M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Navidea Biopharmaceuticals, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Allred Capital Management, LLC | 466,688 | $41.9K | 0.02% | +172,850+58.8% | Added |
| State Street Corp | 412,743 | $37.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 368,830 | $33.1K | 0.00% | +267,832+265.2% | Added |
| Virtu Financial LLC | 333,069 | $30.0K | 0.00% | +333,069 | New |
| Vanguard Group Inc | 276,491 | $24.8K | 0.00% | 00.0% | Unchanged |
| Warberg Asset Management LLC | 194,997 | $17.5K | 0.01% | +194,997 | New |
| UBS Group AG | 149,612 | $13.5K | 0.00% | +149,362+59,744.8% | Added |
| BlackRock Inc. | 113,030 | $10.1K | 0.00% | +102+0.1% | Added |
| Level Four Advisory Services, LLC | 55,555 | $4.98K | 0.00% | +55,555 | New |
| Boothbay Fund Management, LLC | 40,000 | $3.59K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 39,414 | $3.54K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 31,553 | $2.83K | 0.00% | −27,756−46.8% | Reduced |
| Pathstone Family Office, LLC | 10,043 | $900 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 8,937 | $804 | 0.00% | +1,080+13.7% | Added |
| Wells Fargo & Company | 5,632 | $504 | 0.00% | +140+2.5% | Added |
| Morgan Stanley | 4,416 | $396 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 1,604 | $143 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 1,300 | $116 | 0.00% | −1,852−58.8% | Reduced |
| Sound Income Strategies, LLC | 599 | $54 | 0.00% | 00.0% | Unchanged |
| GWM Advisors LLC | 412 | $36 | 0.00% | +412 | New |
| Parallel Advisors, LLC | 350 | $31 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 300 | $27 | 0.00% | 00.0% | Unchanged |
| Kelly Financial Services LLC | 50 | $4 | 0.00% | 00.0% | Unchanged |
| Beacon Capital Management, LLC | 10 | $1 | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −125,866−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −10,003−100.0% | Sold out |
| Northwestern Mutual Wealth Management Co | 0 | $0 | 0.00% | −110−100.0% | Sold out |